Pharmaceutical

Lutetium (lu177) lilotomab satetraxetan by Thor Medical for B-Cell Chronic Lymphocytic Leukemia: Likelihood of Approval

Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.

Aug 28, 2023 - 20:00
Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.
Read the original article

Tags:

Previous Article

Signal: Allina health will no longer bar indebted patients from care

Next Article

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: DeepMind touts AlphaFold’s new skills as protein-folding AI models face off

STAT+: DeepMind touts AlphaFold’s new skills as protein...

Nov 1, 2023

Wane in Covid demand hurts Walgreens as profits drop to $118m

Wane in Covid demand hurts Walgreens as profits drop to...

Jun 27, 2023

STAT+: 4 ways the health care system should shift its thinking on AI, according to experts

STAT+: 4 ways the health care system should shift its t...

May 5, 2023